Dako To Develop Companion Diagnostic for Cancer Therapy

Dako (Glostrup, Denmark) and Genetech Inc. (San Francisco, CA, USA) have signed an agreement for a drug-companion diagnostic codevelopment program for targeted cancer therapy. The collaboration will use Dako's extensive experience in developing cancer diagnostic tests to identify cancer patients who may derive greater benefits from the therapy.

The companies will collaborate on developing a new cancer diagnostic test as a potential companion product for a specific Genentech investigational therapeutic. The collaboration follows Dako's ongoing strategy to combine its strengths with biotechnology and pharmaceutical companies to develop the offering of Dako's pharmacodiagnostic assays.

"We are very pleased to announce our collaboration with Genentech to potentially further expand the market for targeted therapies. We see a great potential in a strong collaborative approach between biotechnology and pharmaceutical companies and diagnostic companies in targeting the right drugs for the right patients, both to improve patient care and more efficiently managing health care costs," said Patrik Dahlen, CEO and president of Dako Denmark.

Dako is a leader in tissue-based cancer diagnostics. Hospital and clinical laboratories use Dako's knowledge, reagents, instruments, and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer.

Genentech, Inc. is a biotechnology company using human genetic information to discover, develop, manufacture, and commercialize biotherapeutics that address medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions.

Related Links:
Dako
Genetech Inc.